Iovance Biotherapeutics
IOVA
228 hedge funds and large institutions have $1.25B invested in Iovance Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 88 increasing their positions, 64 reducing their positions, and 29 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
38% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 29
38% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 64
14% more capital invested
Capital invested by funds: $1.1B → $1.25B (+$158M)
12% more call options, than puts
Call options by funds: $6.36M | Put options by funds: $5.67M
5% more funds holding
Funds holding: 218 → 228 (+10)
17.21% less ownership
Funds ownership: 108.75% → 91.54% (-17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$60.7M |
| 2 |
PA
Perceptive Advisors
New York
|
+$37M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$18.8M |
| 4 |
Morgan Stanley
New York
|
+$18.8M |
| 5 |
O
OrbiMed
New York
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$12.8M |
| 2 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$9.88M |
| 3 |
Renaissance Technologies
New York
|
-$9.14M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$8.06M |
| 5 |
State Street
Boston,
Massachusetts
|
-$6.78M |
IOVA Hedge Fund Activity: Q1 2023 in Review
228 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2023, worth a combined $1.25B — up 14% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new IOVA positions and 29 closed out — a net gain of 11 holders — while 88 added to existing stakes and 64 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $60.7M. The largest seller was D.E. Shaw & Co, cutting an estimated $12.8M.
- 228 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2023, up from 218 in Q4 2022.
- Funds reported $1.25B of Iovance Biotherapeutics stock for Q1 2023, up 14% quarter-over-quarter.
- 40 funds opened new Iovance Biotherapeutics positions in Q1 2023 and 29 closed out, a net change of +11 holders.
- The largest Iovance Biotherapeutics buyer in Q1 2023 was Point72 Asset Management, an estimated $60.7M added.
- The largest Iovance Biotherapeutics seller in Q1 2023 was D.E. Shaw & Co, an estimated $12.8M sold.
Based on aggregated 13F filings for Q1 2023.